Default Mode Network and Depression: Why Psilocybin's DMN Effect Matters

Psilocybin & the Default Mode Network

71% of patients with major depressive disorder responded to psilocybin-assisted therapy

In a 2021 randomized controlled trial published in JAMA Psychiatry, 71% of patients with major depressive disorder responded to psilocybin-assisted therapy, with 54% achieving remission at four weeks. The brain mechanism behind these numbers is now mapped in detail.

Davis AK et al., JAMA Psychiatry, 2021

54%

remission rate at four weeks in the same JAMA Psychiatry trial (Davis et al., 2021, n=24)

p=0.002

significance level at which mystical experience quality during the session predicted 5-week depression outcomes (Roseman et al., Front Pharmacol, 2017, n=20)

>3x

greater brain desynchronization from psilocybin than methylphenidate in the 2024 Nature study; the scale of acute DMN disruption now quantified (Siegel et al., 2024)

Davis AK et al., JAMA Psychiatry, 2021

View as image ↗

One of the clearest findings in neuroimaging research on depression is that the brain's self-referential network becomes not just active but rigid. In major depression, the default mode network (DMN) gets stuck, generating repetitive negative thought loops that resist interruption. Psilocybin appears to specifically target this hyperconnectivity. The fMRI evidence mapping exactly how it does so, and why the resulting antidepressant outcomes compare favorably to first-line medications, now spans more than a decade of controlled research. For a foundational overview of how psilocybin interacts with the DMN, see Psilocybin and the Default Mode Network: How It Quiets the Ego.

Why Depression Gets Stuck: The Hyperactive DMN Problem

In depression, the default mode network becomes hyperconnected and rigid, locking the brain in repetitive negative self-referential thinking known as rumination. Psilocybin disrupts this hyperconnectivity, enables global brain integration, and antidepressant relief correlates with the degree of that disruption.

The default mode network is the brain circuit that activates during internally directed thought: remembering the past, imagining the future, evaluating oneself, constructing a personal narrative. In ordinary cognition, the DMN cycles appropriately. Task demands activate other brain systems, which suppress the DMN. When tasks end, the DMN returns.

In major depression, this cycling breaks down. The network's connectivity becomes excessive and self-amplifying, and the mPFC, the DMN hub that handles self-referential evaluation, stays persistently active not to accomplish useful self-reflection but to generate repetitive negatively valenced content. Rumination is not a failure of willpower. At a mechanistic level, it is a hyperactive DMN problem: a circuit that cannot disengage from its own output.

This model helps explain several otherwise puzzling aspects of depression: why negative thoughts persist even when the person recognizes them as unhelpful, why attempts to reason one's way out of depression so frequently deepen it, and why the most effective psychological interventions for rumination work not by engaging the self-critical content but by interrupting the self-referential circuit itself.

Psilocybin's relevance is specific. Its best-characterized brain effect is disruption of DMN synchronized activity. The research that follows examines whether that disruption specifically targets the rigid DMN hyperconnectivity of depression, and whether it produces lasting relief when it does.

What Psilocybin Does to the Depressed Brain During a Session

In 2017, Carhart-Harris and colleagues published an fMRI study of psilocybin's brain effects in patients with treatment-resistant depression (TRD).^[1] Nineteen patients received two psilocybin sessions (10 mg and 25 mg, one week apart) with psychological support; quality pre- and post-treatment fMRI data were collected from 16 of the 19. All 19 showed reduced depressive symptoms at 1 week, and 47% met response criteria at 5 weeks.

The post-treatment fMRI findings were specific. Whole-brain analyses showed decreased cerebral blood flow in the temporal cortex, including the amygdala, and decreased amygdala CBF correlated with reduced depressive symptoms.^[1] A priori resting-state functional connectivity analyses showed increased RSFC within the default-mode network at 1 day post-treatment. Two specific connectivity changes predicted 5-week response: increased ventromedial prefrontal cortex–bilateral inferior parietal cortex RSFC and decreased parahippocampal–prefrontal cortex RSFC.^[1]

This 2017 paper is a paradox-laden snapshot rather than a clean "DMN goes quiet, recovery follows" story. Within-DMN connectivity went up, not down, in the day after treatment. The amygdala signal that tracked recovery was reduced cerebral blood flow, not increased reactivity. The cleaner "global integration" interpretation of psilocybin's antidepressant action came later, in Daws 2022, where data from this trial and the Carhart-Harris 2021 NEJM trial were pooled. For a closer examination of the mechanistic sequence step by step, see what happens when the DMN goes offline.

The contrast with SSRIs is instructive at a mechanistic level. SSRIs modulate serotonin availability chronically through daily dosing, producing gradual receptor sensitivity changes over weeks. Psilocybin produces a single acute disruption of DMN connectivity that appears to trigger lasting network reorganization. One mechanism works through accumulation; the other through an acute reset that persists.

Why Depression Recovery Tracks Global Integration, Not Just DMN Suppression

A 2022 Nature Medicine paper by Daws and colleagues refined the mechanistic picture considerably. Using fMRI data from the Carhart-Harris 2021 NEJM psilocybin trial (59 participants), they identified the specific brain biomarker that predicted antidepressant response over six weeks.^[2]

That biomarker was not DMN suppression alone. It was global brain integration: the degree to which brain networks that had previously been functionally isolated from each other began to communicate after psilocybin treatment.

In depression, the brain exhibits high modularity. Each functional network, the DMN, the executive control network, the salience network, operates in relative isolation with limited cross-network communication. This modularity is part of what makes depressed cognition feel locked. The ruminative loop stays within the DMN without interference from networks that might interrupt or redirect it.

After psilocybin, the Daws 2022 paper found that this modularity decreased.^[2] The DMN's rigid boundaries dissolved. Networks that had been functionally separate began to communicate. The degree to which this global integration emerged tracked directly with the degree of symptom improvement over six weeks.

This is a meaningful conceptual refinement. "Psilocybin suppresses the DMN" describes only part of what happens. The fuller description: psilocybin disrupts the DMN's rigid dominance and, in that disruption, enables new cross-network connections. The therapeutic action is not just silencing the rumination loop. It is opening the isolated DMN to broader brain communication, which, according to the Daws data, appears to be what actually resolves the depressive state.

The flip side of this, the emergence of new cross-network connections as the DMN loses its isolation, is covered in depth at Psilocybin and Brain Connectivity: The Hyperconnected Brain.

Psilocybin vs. Escitalopram: What the NEJM Head-to-Head Trial Found

In 2021, Carhart-Harris and colleagues published a randomized controlled trial in the New England Journal of Medicine comparing two sessions of psilocybin (25mg per session, three weeks apart) against a six-week course of escitalopram, a commonly prescribed SSRI, in 59 patients with moderate-to-severe depression.^[3]

On the primary endpoint, the Quick Inventory of Depressive Symptomatology (QIDS-SR-16) at six weeks, psilocybin was non-inferior to escitalopram. Both treatments produced similar reductions in depressive symptoms.^[3]

The non-inferiority result understates the picture on secondary outcomes. Participants who received psilocybin reported significantly greater improvements in well-being, sense of meaning in life, and sexual function at six weeks. These are not peripheral metrics. For many people with depression, diminished sense of meaning and sexual dysfunction are central features of the condition, and the domains where existing antidepressants are weakest.^[3]

The trial was not powered to establish superiority; 59 participants is adequate to test non-inferiority but not to detect moderate advantages on secondary outcomes reliably. The secondary findings suggest potentially meaningful advantages that would require larger trials to confirm. The Carhart-Harris 2021 study is best read as establishing legitimacy: psilocybin holds its own against a first-line SSRI in a direct comparison, with a meaningfully different profile of effects.

The mechanism behind this different profile connects back to the Daws 2022 global integration finding. SSRIs produce incremental, chronic serotonin modulation; psilocybin produces a single massive event of network reorganization. That a one-time experience in a supported setting might produce different subjective outcomes from six weeks of daily medication is not surprising. The question is whether the brain-level distinction corresponds to a clinically meaningful patient-level difference, and the NEJM data suggests it may.

The Clinical Numbers: 71%, 80%, and 83% Response Rates Across Three Trials

The response rate data from psilocybin depression trials is among the most striking in contemporary clinical psychiatry, particularly given that many trials targeted populations where standard treatments had already failed or were limited.

Davis and colleagues' 2021 JAMA Psychiatry trial enrolled patients with primary major depressive disorder, without the life-threatening cancer diagnosis that had constrained earlier trials.^[4] Twenty-seven participants were randomized to either immediate treatment (n = 15) or an eight-week delay (n = 12); 24 of 27 completed the intervention and the week-1 and week-4 post-session assessments and made up the evaluable population. In the overall sample, 17 participants (71%) at week 1 and 17 (71%) at week 4 met response criteria (≥ 50% reduction in GRID-HAMD), and 14 (58%) at week 1 and 13 (54%) at week 4 were in remission (GRID-HAMD ≤ 7). Effect sizes versus the delayed treatment comparison were large (Cohen d = 2.5–2.6, P < .001). No serious adverse events were reported.^[4]

Griffiths and colleagues' 2016 trial at Johns Hopkins enrolled 51 patients with cancer-related depression and anxiety, a population with high rates of treatment-resistant symptoms and significant psychological burden.^[5] The study used a double-blind crossover design with high-dose psilocybin and an active placebo control. At six-month follow-up, 80% of participants showed clinically significant antidepressant response. Effect sizes exceeded 1.0 relative to placebo, values rarely seen in antidepressant trials. The study also found that psilocybin-occasioned mystical experience statistically mediated the antidepressant effect, providing a direct mechanistic link between the subjective experience and the clinical outcome.^[5]

Ross and colleagues' 2016 NYU trial enrolled 29 patients with cancer-related anxiety and depression in a double-blind crossover design.^[6] At six weeks, 83% of participants who had received psilocybin showed significant antidepressant response, compared to 14% in the active placebo condition. Between 60% and 80% maintained their response at 6.5-month follow-up. The rapid onset, one session producing measurable effects within weeks, distinguished the mechanism from conventional antidepressants that typically require four to eight weeks of daily dosing before therapeutic effects emerge.^[6]

These three trials differ in population, design, and primary endpoints. What they share: single-session or two-session psilocybin treatment producing response rates in a range that typical SSRI trials do not approach, with effects that persist at follow-up months later. The consistency of this pattern across independent research groups is a meaningful signal even given each study's limited sample size.

Why the Quality of Ego Dissolution During the Session Predicts 5-Week Outcomes

Roseman, Nutt, and Carhart-Harris published a 2017 analysis in Frontiers in Pharmacology examining, in 20 patients with treatment-resistant depression who had received psilocybin, whether the subjective quality of the session experience predicted depression outcomes at five weeks.^[7]

The analysis used the States of Consciousness Questionnaire to measure two distinct experiential dimensions during the session. Oceanic Boundlessness (OBN) is the positive component of ego dissolution: feelings of unity, timelessness, and dissolution of the boundary between self and world. Dread of Ego Dissolution (DED) is the anxious or frightening component: fear of loss of identity, loss of control, and psychological fragmentation.

Oceanic Boundlessness predicted five-week depression outcomes with p=0.002. The depth of the positive mystical state during the session specifically predicted how much better patients felt five weeks later.^[7]

Dread of Ego Dissolution also predicted outcomes at p=0.003. This is the less intuitive finding. The challenging, frightening aspects of the ego dissolution experience also predicted better outcomes, not worse. Patients who experienced more DED during the session did not have worse results; they had better ones.^[7]

The implication: the session experience is not incidental to the therapeutic effect. Both its positive and difficult dimensions predict recovery. The subjective state during the session, specifically its ego-dissolution qualities, directly predicts the clinical outcome weeks later.

This connects the DMN mechanism to the therapeutic outcome through a specific pathway. Psilocybin disrupts DMN connectivity, producing ego dissolution. The depth of that ego dissolution, positive and challenging alike, predicts antidepressant response. If the mystical state predicts recovery and that state reflects the DMN decoupling psilocybin produces, then the mechanism of antidepressant action appears to run through the quality of consciousness during the session itself.

For the full analysis of how Oceanic Boundlessness and the Dread of Ego Dissolution each relate to therapeutic outcome, and how 5-HT2A receptor density determines the depth of the mystical state, see the relationship between DMN disruption and mystical experience. For the neurobiological account of how ego dissolution is measured and what it looks like in brain scans, see psilocybin and ego dissolution.

Who Responds Best? Baseline Brain Scans May Offer Predictions

Copa and colleagues published a 2024 analysis addressing a practical clinical question: can pre-treatment brain imaging predict who will respond to psilocybin for depression?^[8]

The team built a machine-learning pipeline on baseline resting-state fMRI from 16 patients with treatment-resistant depression in a psilocybin monotherapy trial, and tested generalization in a second cohort of 22 participants from the Carhart-Harris 2021 psilocybin-vs-escitalopram trial. Functional connectivity of the visual, default mode and executive networks predicted early symptom improvement, while salience-network connectivity predicted responders up to 24 weeks after treatment with reported accuracy of approximately 0.9.^[8]

The interesting clinical implication is that pre-treatment fMRI patterns may carry signal about who is likeliest to benefit from psilocybin therapy. The samples here are small (16 + 22), the analysis uses cross-validated machine learning rather than independent replication in a fully separate cohort, and the salience-network finding in particular needs prospective replication before any of this becomes a clinical-decision tool. The existence of a brain-based predictor at all is the scientifically significant point; the size of that signal in routine practice is not yet established.

A 2024 Nature study by Siegel and colleagues adds one more dimension to understanding why psilocybin's effects in depression can persist.^[9] Dense-sampling fMRI showed hippocampal-DMN functional connectivity remained decreased for weeks after a single psilocybin session, well beyond the acute drug effect. The hippocampus is central to memory consolidation and contextual learning. Its sustained disconnection from the DMN after psilocybin may provide the neurobiological substrate for the consolidation of new psychological perspectives that the acute session makes available. The window stays open longer than the experience itself.

For the full account of what brain scans reveal about the specific neurobiological mechanisms underlying psilocybin's antidepressant action, see what brain scans reveal about how psilocybin treats depression.

The Bottom Line

The case for psilocybin as an antidepressant is now neurobiologically grounded. The hyperactive DMN that characterizes depression is specifically targeted by psilocybin's acute effects; post-treatment brain scans show the opposite pattern from baseline, with increased rather than decreased connectivity. The therapeutic biomarker that best predicts recovery is not DMN suppression alone but global brain integration: networks previously isolated from each other begin to communicate, and the degree of that communication tracks with symptom improvement. Clinically, three major RCTs have reported 71-83% response rates with effects persisting months after one or two sessions, and a head-to-head NEJM trial found psilocybin non-inferior to escitalopram with advantages on well-being outcomes. The quality of the session experience, specifically the depth of ego dissolution, predicts how much better patients feel weeks later, suggesting the subjective experience is not incidental but mechanistically central to the therapeutic effect.

Frequently Asked Questions

Why is the default mode network overactive in depression?

In depression, the brain's self-referential circuit becomes hyperconnected and rigid, generating repetitive negative self-evaluative thought that resists interruption. The medial prefrontal cortex, the DMN's primary hub for self-referential processing, stays persistently active rather than cycling appropriately with task demands. This hyperactivity is the neural mechanism of rumination: the circuit cannot disengage from negative content, reinforcing it rather than processing and releasing it. Neuroimaging research consistently finds elevated DMN connectivity in major depressive disorder, and the degree of DMN hyperconnectivity correlates with depression severity.

Does psilocybin permanently change the default mode network?

The current evidence shows lasting but not permanently characterized changes. Post-treatment fMRI in 20 treatment-resistant depression patients found increased brain network connectivity persisting at five weeks (Carhart-Harris et al., Scientific Reports, 2017). A 2024 Nature study found hippocampal-DMN connectivity remained decreased for weeks after a single psilocybin session (Siegel et al., n=7). A 2022 Nature Medicine analysis found global brain integration changes that tracked symptom improvement over six weeks (Daws et al., n=59). Whether these changes persist beyond these follow-up windows is not established by existing imaging studies. What is clear is that a single session produces measurable neurobiological changes lasting well beyond the acute drug effect.

How does psilocybin treat depression differently than antidepressants?

SSRIs modulate serotonin availability chronically through daily dosing, producing gradual receptor sensitivity changes over weeks. Psilocybin produces a single massive disruption of DMN functional connectivity during a 4-6 hour session that appears to trigger lasting network reorganization. A 2022 Nature Medicine analysis found the therapeutic biomarker was global brain integration, specifically previously isolated networks beginning to communicate, rather than any single neurotransmitter parameter (Daws et al., n=59). In the NEJM head-to-head trial (n=59), psilocybin performed comparably to escitalopram on the primary depression endpoint and significantly better on well-being and meaning in life at six weeks (Carhart-Harris et al., 2021).

What does the default mode network have to do with depression?

The default mode network is the brain circuit most directly linked to self-referential thought, including the negative self-evaluation and rumination that characterize depression. In a healthy brain, the DMN activates during rest and appropriate self-reflection and suppresses when tasks demand focused attention. In depression, the DMN becomes hyperactive and rigid, generating persistent negative self-referential content that the brain cannot interrupt; this is the neural substrate of rumination. Psilocybin's primary documented brain effect is disruption of this DMN hyperconnectivity, and the degree of network reorganization after treatment correlates directly with symptom improvement (Daws et al., Nature Medicine, 2022, n=59).

How long do psilocybin's effects on depression last?

Across major trials, antidepressant effects have persisted at follow-up periods ranging from weeks to months. Davis et al. (JAMA Psychiatry, 2021) found 71% response and 54% remission at week 4 in the evaluable population (24 of 27 randomized). Griffiths et al. (J Psychopharmacology, 2016) found 80% response at six-month follow-up in cancer patients (n=51). Ross et al. (J Psychopharmacology, 2016) found 60-80% of responders maintained response at 6.5-month follow-up (n=29). A 2024 Nature study found hippocampal-DMN connectivity changes persisting for weeks after a single session (Siegel et al.). How long effects last beyond these follow-up windows and whether maintenance sessions extend benefits are active research questions.

Sources & References

1. 1RTHM-00463·Carhart-Harris, Robin L et al. (2017). “Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms..” Scientific reports.Study breakdown →PubMed →↩
2. 2RTHM-00752·Daws, Richard E et al. (2022). “Increased global integration in the brain after psilocybin therapy for depression..” Nature medicine.Study breakdown →PubMed →↩
3. 3RTHM-00675·Carhart-Harris, Robin et al. (2021). “Trial of Psilocybin versus Escitalopram for Depression..” The New England journal of medicine.Study breakdown →PubMed →↩
4. 4RTHM-00682·Davis, Alan K et al. (2021). “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial..” JAMA psychiatry.Study breakdown →PubMed →↩
5. 5RTHM-00426·Griffiths, Roland R et al. (2016). “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
6. 6RTHM-00445·Ross, Stephen et al. (2016). “Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
7. 7RTHM-00907·Roseman, Leor et al. (2017). “Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression..” Frontiers in pharmacology.Study breakdown →PubMed →↩
8. 8RTHM-00872·Copa, Débora et al. (2024). “Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity..” Journal of affective disorders.Study breakdown →PubMed →↩
9. 9RTHM-00911·Siegel, Joshua S et al. (2024). “Psilocybin desynchronizes the human brain..” Nature.Study breakdown →PubMed →↩